GSBS Student Publications

Title

Early HIV-1 envelope-specific cytotoxic T lymphocyte responses in vertically infected infants

UMMS Affiliation

Graduate School of Biomedical Sciences; Department of Pediatrics; Program in Molecular Medicine

Date

4-7-1997

Document Type

Article

Medical Subject Headings

Cloning, Molecular; Cross Reactions; Disease Progression; Disease Transmission, Vertical; Gene Products, env; Genes, env; HIV Infections; HIV-1; Hematopoietic Stem Cells; Humans; Infant; Infant, Newborn; Polymerase Chain Reaction; T-Lymphocytes, Cytotoxic; Time Factors

Disciplines

Life Sciences | Medicine and Health Sciences

Abstract

High frequencies of cytotoxic T lymphocyte precursors (CTLp) recognizing HIV-1 laboratory strain gene products have been detected in adults within weeks of primary infection. In contrast, HIV-1-specific CTLp are uncommonly detected in infants younger than 6 mo. To address the hypothesis that the use of target cells expressing laboratory strain env gene products might limit the detection of HIV-1 env-specific CTLp in early infancy, recombinant vaccinia vectors (vv) expressing HIV-1 env genes from early isolates of four vertically infected infants were generated. The frequencies of CTLp recognizing target cells infected with vv-expressing env gene products from early isolates and HIV-1 IIIB were serially measured using limiting dilution followed by in vitro stimulation with mAb to CD3. In one infant, the detection of early isolate env-specific CTLp preceded the detection of IIIB-specific CTLp. CTLp recognizing HIV-1 IIIB and infant isolate env were detected by 6 mo of age in two infants. In a fourth infant, HIV-1 IIIB env and early isolate env-specific CTLp were simultaneously detected at 12 mo of age. These results provide evidence that young infants can generate HIV-1-specific CTL responses and provide support for the concept of neonatal vaccination to prevent HIV-1 transmission. However, the early predominance of type-specific CTL detected in some young infants suggests that the use of vaccines based on laboratory strains of HIV-1 may not protect against vertical infection.

Rights and Permissions

Citation: J Exp Med. 1997 Apr 7;185(7):1153-61.

Related Resources

Link to article in PubMed

Journal Title

The Journal of experimental medicine

PubMed ID

9104802